MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling tr… Read more
MIRA Pharmaceuticals, Inc. Common Stock (MIRA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.145x
Based on the latest financial reports, MIRA Pharmaceuticals, Inc. Common Stock (MIRA) has a cash flow conversion efficiency ratio of -0.145x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.10 Million) by net assets ($7.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MIRA Pharmaceuticals, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how MIRA Pharmaceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
MIRA Pharmaceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MIRA Pharmaceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LHYFE S.A. EO -01
F:F1B
|
N/A |
|
Tecnotree Oyj
HE:TEM1V
|
0.035x |
|
Ihlas Gayrimenkul Proje Gelistirme ve Ticaret AS
IS:IHLGM
|
-0.001x |
|
C-Tech United
TWO:3625
|
-0.090x |
|
Midwest Energy Emiss
OTCQB:MEEC
|
-0.080x |
|
Miwon Chemical
KO:134380
|
0.065x |
|
Turnkey Communication Services PCL
BK:TKC
|
-0.028x |
|
Vocento
MC:VOC
|
-0.045x |
Annual Cash Flow Conversion Efficiency for MIRA Pharmaceuticals, Inc. Common Stock (2020–2024)
The table below shows the annual cash flow conversion efficiency of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.20 Million | $-5.56 Million | -2.528x | -143.97% |
| 2023-12-31 | $4.37 Million | $-4.53 Million | -1.036x | -111.02% |
| 2022-12-31 | $-596.23K | $-5.60 Million | 9.400x | +1644.70% |
| 2021-12-31 | $2.26 Million | $-1.38 Million | -0.609x | -160.86% |
| 2020-12-31 | $-67.99K | $-67.99K | 1.000x | -- |